Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH

Modern Pathology

Volumn 29, Issue 8, 2016, Pages 904-914

  Lotan, Tamara L ^a   Wei, Wei ^b   Ludkovski, Olga ^c   Morais, Carlos L ^a   Guedes, Liana B ^a   Jamaspishvili, Tamara ^c   Lopez, Karen ^d   Hawley, Sarah T ^e   Feng, Ziding ^b   Fazli, Ladan ^f   Hurtado Coll, Antonio ^f   McKenney, Jesse K ^g   Simko, Jeffrey ^d   Carroll, Peter R ^d   Gleave, Martin ^e   Lin, Daniel W ^h   Nelson, Peter S ^h,i   Thompson, Ian M ^j   True, Lawrence D ^h   Brooks, James D ^k   Lance, Raymond ^l   Troyer, Dean ^l   Squire, Jeremy A ^c,m   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c QUEEN S UNIVERSITY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Canary Foundation   (United States)

^f VANCOUVER PROSTATE CENTRE   (Canada)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^m UNIVERSITY OF SÃO PAULO   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; BRITISH COLUMBIA; CLINICAL TRIAL; COMPARATIVE STUDY; ENZYMOLOGY; GENE DOSAGE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; MULTICENTER STUDY; PATHOLOGY; PHENOTYPE; PROSTATE TUMOR; REPRODUCIBILITY; RETROSPECTIVE STUDY; TISSUE MICROARRAY; UNITED STATES; VALIDATION STUDY;

BIOMARKERS, TUMOR; BRITISH COLUMBIA; GENE DELETION; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; UNITED STATES;

EID: 84968538157     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.88     Document Type: Article

References (36)

1. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-220.
2. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-689.
3. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-243.
4. Beltran H, Yelensky R, Frampton GM, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013; 63: 920-926.
5. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161: 1215-1228.
6. Yoshimoto M, Cunha IW, Coudry RA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007; 97: 678-685.
7. McCall P, Witton CJ, Grimsley S, Nielsen KV, Edwards J. Is PTEN loss associated with clinical outcome measures in human prostate cancer?. Br J Cancer 2008; 99: 1296-1301.
8. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008; 21: 1451-1460.
9. Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011; 17: 6563-6573.
10. Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012; 181: 401-412.
11. Antonarakis ES, Keizman D, Zhang Z, et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 2012; 118: 6063-6071.
12. Chaux A, Peskoe SB, Gonzalez-Roibon N, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol 2012; 25: 1543-1549.
13. Steurer S, Mayer PS, Adam M, et al. TMPRSS2-ERG fusions are strongly linked to young patient age in lowgrade prostate cancer. Eur Urol 2014; 66: 978-981.
14. Cuzick J, Yang ZH, Fisher G, et al. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer 2013; 108: 2582-2589.
15. Liu W, Xie CC, Thomas CY, et al. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer 2013; 119: 2405-2412.
16. Mithal P, Allott E, Gerber L, et al. PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer. Int J Pathol 2014; 21: 1209-1214.
17. Troyer DA, Jamaspishvili T, Wei W, et al. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate 2015; 75: 1206-1215.
18. Ahearn TU, Pettersson A, Ebot EM, et al. A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer. J Natl Cancer Inst 2016; 108.
19. Sangale Z, Prass C, Carlson A, et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol 2011; 19: 173-183.
20. Gumuskaya B, Gurel B, Fedor H, et al. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion. Prostate Cancer Prostatic Dis 2013; 16: 209-215.
21. Bismar TA, Yoshimoto M, Duan Q, et al. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer. Histopathology 2012; 60: 645-652.
22. Krohn A, Freudenthaler F, Harasimowicz S, et al. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Mod Pathol 2014; 27: 1612-1620.
23. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22: 1083-1093.
24. Verhagen PC, van Duijn PW, Hermans KG, et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-Allelic gene deletion. J Pathol 2006; 208: 699-707.
25. Poliseno L, Salmena L, Zhang J, et al. A codingindependent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010; 465: 1033-1038.
26. Lotan TL, Wei W, Morais CL, et al. PTEN loss as determined by clinical-grade immunohistochemistry assay is associated with worse recurrence-free survival in prostate cancer. Eur Urol Focus 2016 (in press
27. Hawley S, Fazli L, McKenney JK, et al. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol 2013; 20: 39-44.
28. Lotan TL, Carvalho FL, Peskoe SB, et al. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol 2015; 28: 128-137.
29. Yoshimoto M, Ludkovski O, DeGrace D, et al. PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes Cancer 2012; 51: 149-160.
30. Sircar K, Yoshimoto M, Monzon FA, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009; 218: 505-513.
31. Reid AH, Attard G, Ambroisine L, et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010; 102: 678-684.
32. Poliseno L, Salmena L, Riccardi L, et al. Identification of themiR-106b~25 microRNA cluster as a proto-oncogenic PTEN-Targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 2010; 3: ra29.
33. Ugalde-Olano A, Egia A, Fernandez-Ruiz S, et al. Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN. Methods 2015; 77-78: 25-30.
34. Yoshimoto M, Cutz JC, Nuin PA, et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006; 169: 128-137.
35. Ferraldeschi R, Nava Rodrigues D, Riisnaes R, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol 2015; 67: 795-802.
36. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.